Sökning: onr:"swepub:oai:gup.ub.gu.se/299424" >
Value of flow cytom...
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
-
- Modvig, S (författare)
- Copenhagen University Hospital,Vilnius University,Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.,Vilnius Univ Hosp, Santaros Klin, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania.
-
- Hallböök, Helene (författare)
- Uppsala universitet,Uppsala University,Copenhagen University Hospital,Oslo university hospital,Hematologi,Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.,Oslo Univ Hosp, Dept Pathol, Lab Mol Pathol, Oslo, Norway.
-
- Madsen, H O (författare)
- Umeå University,Umeå Univ, Dept Med Biosci, Pathol, Umeå, Sweden.
-
visa fler...
-
- Siitonen, S (författare)
- University of Helsinki,University of Copenhagen,Univ Helsinki, Clin Chem, Helsinki, Finland.;Helsinki Univ Hosp, Helsinki, Finland.,Univ Copenhagen, Sect Biostat, Copenhagen, Denmark.
-
Rosthøj, S (författare)
-
- Tierens, A (författare)
- University of Toronto,Oslo university hospital,Univ Hlth Network, Lab Med Program, Toronto, ON, Canada.;Univ Toronto, Toronto, ON, Canada.;Univ Hosp Oslo, Dept Pathol, Oslo, Norway.
-
- Juvonen, V (författare)
- University of Turku,Univ Turku, Dept Clin Chem, Turku, Finland.;Univ Turku, Lab Div, Turku, Finland.;Turku Univ Hosp, Turku, Finland.
-
- Osnes, L T N (författare)
- Oslo university hospital,Herlev Hospital,Oslo Univ Hosp, Dept Immunol, Oslo, Norway.,Herlev Univ Hosp, Dept Hematol, Herlev, Denmark.
-
Vålerhaugen, H (författare)
-
- Hultdin, Magnus (författare)
- Umeå universitet,Patologi
-
- Matuzeviciene, R (författare)
- Vilnius University,Vilnius Univ, Inst Biomed Sci, Fac Med, Dept Physiol Biochem Microbiol & Lab Med, Vilnius, Lithuania.;Vilnius Univ Hosp, Santaros Klin, Ctr Lab Med, Vilnius, Lithuania.
-
Stoskus, M (författare)
-
- Ehinger, M. (författare)
- Lund University,Lunds universitet,Uppsala University,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Skane Univ Hosp, Dept Clin Genet & Pathol, Lund, Sweden.;Lund Univ, Dept Clin Sci Oncol & Pathol, Lund, Sweden.
-
- Lilleorg, A (författare)
- North Estonia Medical Centre,North Estonia Med Ctr, Dept Clin Immunol, Tallinn, Estonia.
-
Ehinger, M (författare)
-
- Norén-Nyström, Ulrika (författare)
- Umeå University,Umeå universitet,Pediatrik,Umeå Univ, Dept Clin Sci, Pediat, Umeå, Sweden.
-
Toft, N (författare)
-
- Taskinen, M (författare)
- Helsinki University Central Hospital,Helsinki Univ Hosp, Div Pediat Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland.
-
- Jónsson, O G (författare)
- National University Hospital of Iceland,Landspitali Univ Hosp, Childrens Hosp, Reykjavik, Iceland.
-
- Pruunsild, K (författare)
- Tallinn Children's Hospital,Tallinn Childrens Hosp, Tallinn, Estonia.
-
- Vaitkeviciene, G (författare)
- Vilnius University,Vilnius Univ Hosp, Santariskiu Klin, Childrens Hosp, Vilnius, Lithuania.
-
- Vettenranta, K (författare)
- University of Helsinki,Univ Helsinki, Helsinki, Finland.;Univ Helsinki, Childrens Hosp, Helsinki, Finland.
-
- Lund, B (författare)
- St. Olav’s University Hospital,St Olavs Univ Hosp, Dept Pediat, Trondheim, Norway.;NTNU, Dept Clin & Mol Med, Trondheim, Norway.
-
- Abrahamsson, Jonas, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics,Sahlgrenska University Hospital,Sahlgrens Univ Hosp, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden.
-
- Porwit, A. (författare)
- Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Fac Med, Dept Clin Sci, Div Oncol & Pathol, Lund, Sweden.
-
- Schmiegelow, K (författare)
- Copenhagen University Hospital,Copenhagen Univ Hosp, Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark.;Univ Copenhagen, Inst Clin Med, Fac Med, Copenhagen, Denmark.
-
Marquart, H V (författare)
-
- Marincevic, Millaray, 1983- (författare)
- Uppsala universitet,Klinisk och experimentell patologi
-
visa färre...
-
(creator_code:org_t)
- 2020-12-14
- 2021
- Engelska.
-
Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 35, s. 1894-1906
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://doi.org/10.1...
-
https://umu.diva-por... (primary) (Raw object)
-
http://dx.doi.org/10... (free)
-
https://uu.diva-port... (primary) (Raw object)
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p<0.0001), 29 (HzR 2.7, p<0.0001), and 79 (HzR 3.5, p<0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4×10-2 versus 5.2×10-3, p<0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y=3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD>10-4 associated with a CIR5y=22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Pediatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Pediatrics (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Leukemia
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Modvig, S
-
Hallböök, Helene
-
Madsen, H O
-
Siitonen, S
-
Rosthøj, S
-
Tierens, A
-
visa fler...
-
Juvonen, V
-
Osnes, L T N
-
Vålerhaugen, H
-
Hultdin, Magnus
-
Matuzeviciene, R
-
Stoskus, M
-
Ehinger, M.
-
Lilleorg, A
-
Ehinger, M
-
Norén-Nyström, U ...
-
Toft, N
-
Taskinen, M
-
Jónsson, O G
-
Pruunsild, K
-
Vaitkeviciene, G
-
Vettenranta, K
-
Lund, B
-
Abrahamsson, Jon ...
-
Porwit, A.
-
Schmiegelow, K
-
Marquart, H V
-
Marincevic, Mill ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Pediatrik
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Leukemia
- Av lärosätet
-
Göteborgs universitet
-
Umeå universitet
-
Lunds universitet
-
Uppsala universitet